Capital Bank & Trust Co boosted its holdings in Merck & Co., Inc. (NYSE:MRK) by 36.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 380,478 shares of the company’s stock after purchasing an additional 102,300 shares during the period. Capital Bank & Trust Co’s holdings in Merck & Co., Inc. were worth $24,362,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Perennial Advisors LLC increased its position in Merck & Co., Inc. by 10.7% in the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after buying an additional 157 shares during the period. Stelac Advisory Services LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $104,000. NewSquare Capital LLC increased its position in shares of Merck & Co., Inc. by 728.3% during the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock valued at $115,000 after purchasing an additional 13,014 shares during the period. Solaris Asset Management LLC increased its position in shares of Merck & Co., Inc. by 6.3% during the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after purchasing an additional 115 shares during the period. Finally, Barnett & Company Inc. increased its position in shares of Merck & Co., Inc. by 481.6% during the second quarter. Barnett & Company Inc. now owns 2,053 shares of the company’s stock valued at $132,000 after purchasing an additional 1,700 shares during the period. 73.24% of the stock is currently owned by institutional investors.
In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 5,000 shares of the company’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $58.00, for a total value of $290,000.00. Following the sale, the insider now directly owns 101,484 shares in the company, valued at $5,886,072. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael J. Holston sold 12,500 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total value of $770,375.00. The disclosure for this sale can be found here. Insiders sold 77,500 shares of company stock worth $4,758,175 over the last quarter. Company insiders own 0.25% of the company’s stock.
Shares of Merck & Co., Inc. (MRK) opened at $55.88 on Thursday. Merck & Co., Inc. has a 1 year low of $53.63 and a 1 year high of $66.80. The firm has a market capitalization of $152,240.00, a price-to-earnings ratio of 60.09, a price-to-earnings-growth ratio of 2.51 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Merck & Co., Inc. had a return on equity of 27.73% and a net margin of 6.40%. The firm had revenue of $10.43 billion for the quarter, compared to analysts’ expectations of $10.48 billion. During the same period in the prior year, the business posted $0.89 earnings per share. The business’s revenue was up 3.1% compared to the same quarter last year. equities research analysts anticipate that Merck & Co., Inc. will post 4.18 EPS for the current fiscal year.
Merck & Co., Inc. announced that its Board of Directors has authorized a share repurchase plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 6th. Shareholders of record on Thursday, March 15th will be given a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date of this dividend is Wednesday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 206.45%.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.